TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT01281878

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vitamin B 6
Description: Oral solution of pyridoxal phosphate start with 5mg per kg body weight per day in two dosages over 6 weeks, increase stepwise by 5mg/kg body weight every 6 weeks up to 20 mg/kg body weight/d.
Study: NCT04129034

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Neurolyser XR
Description: Non-Invasive Thermal Ablation of the Medial Branch Nerves
Study: NCT02094430

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: biological: human fibrinogen concentrate
Study: NCT01528878

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Stereotactic Radiosurgery using the CyberKnife System.
Description: Radiation: Stereotactic Radiosurgery using the CyberKnife System. The CyberKnife system has been cleared by the U.S. Food and Drug Administration (FDA) to treat lesions, tumors and conditions, anywhere in the body when radiation treatment is indicated. To address movement of target lesion during the respiratory cycle, the Synchrony™ option will be used.~The Synchrony option precisely tracks tumors in or near the target organ as they move, enabling the highly focused beams of radiation to destroy the tumors with minimal injury to adjacent normal tissue. The Synchrony option records the breathing movements of a patient's chest and combines that information with sequential x-ray pictures of tiny markers inserted inside or in the proximity of the tumor to enable precise delivery of radiation during any point in the respiration cycle. The CyberKnife system with the Synchrony option enables reduced normal tissue exposure by using smaller treatment margins and increased accuracy.

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Stereotactic Radiosurgery using the CyberKnife System.
Description: Radiation: Stereotactic Radiosurgery using the CyberKnife System. The CyberKnife system has been cleared by the U.S. Food and Drug Administration (FDA) to treat lesions, tumors and conditions, anywhere in the body when radiation treatment is indicated. To address movement of target lesion during the respiratory cycle, the Synchrony™ option will be used.~The Synchrony option precisely tracks tumors in or near the target organ as they move, enabling the highly focused beams of radiation to destroy the tumors with minimal injury to adjacent normal tissue. The Synchrony option records the breathing movements of a patient's chest and combines that information with sequential x-ray pictures of tiny markers inserted inside or in the proximity of the tumor to enable precise delivery of radiation during any point in the respiration cycle. The CyberKnife system with the Synchrony option enables reduced normal tissue exposure by using smaller treatment margins and increased accuracy.
Study: NCT01852773

Intervention type: PROCEDURE
Intervention: Open repair of thoracic aorta injury
Description: open surgical management of aortic injury

Intervention type: PROCEDURE
Intervention: TEVAR
Description: Use of endovascular (minimally invasive) techniques for repair of aortic injury
Study: NCT01875133

Intervention type: OTHER
Group type: OTHER
Intervention: altitude exposure
Description: stay at different altitudes: 490, 1630, 2590 m
Study: NCT04273633

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Placebo comparator
Description: To simulate a 448kilohertz capacitive resistive monopolar radiofrequency application on the dominant shoulder
Study: NCT03787940

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Isoniazid
Description: standard dose isoniazid or high dose isoniazid for participants with rapid acetylators
Study: NCT01875133

Intervention type: OTHER
Group type: OTHER
Intervention: altitude exposure
Description: stay at different altitudes: 490, 1630, 2590 m

Intervention type: OTHER
Group type: OTHER
Intervention: altitude exposure
Description: stay at different altitudes: 490, 1630, 2590 m

Intervention type: OTHER
Group type: OTHER
Intervention: altitude exposure
Description: stay at different altitudes: 490, 1630, 2590 m
Study: NCT05089240

Intervention type: DEVICE
Group type: OTHER
Intervention: Ophthalmic lens with extra power

Intervention type: DEVICE
Group type: OTHER
Intervention: Ophthalmic lens with extra power

Intervention type: DEVICE
Group type: OTHER
Intervention: Ophthalmic lens with extra power
Study: NCT03670407

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Ovarian tissue fragmentation
Description: Unilateral ovariectomy, ovarian tissue in vitro fragmentation and reimplantation.
Study: NCT02413905

Intervention type: BIOLOGICAL
Intervention: Stool samples
Description: Stool samples

Intervention type: BIOLOGICAL
Intervention: Stool samples
Description: Stool samples
Study: NCT04746287

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CKD-510 single dose
Description: Investigational drug

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CKD-510 food effect
Description: Investigational drug
Study: NCT00033631

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: 70.2 Gy 3D-CRT/IMRT
Description: Radiation will be delivered via 3D conformal radiation therapy (3D-CRT) or intensity modulated radiation therapy (IMRT) in 1.8 Gy minimum dose fractions to a total of 70.2 Gy in 39 Fractions. All fields treated once daily, five fractions per week. No more than 2% of the planning target volume and none of the clinical target volume may receive less than 70.2 Gy.

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: 79.2 Gy 3D-CRT/IMRT
Description: Radiation will be delivered via 3D conformal radiation therapy (3D-CRT) or intensity modulated radiation therapy (IMRT) in 1.8 Gy minimum dose fractions to a total of 79.2 Gy in 44 fractions. All fields treated once daily, five fractions per week. No more than 2% of the planning target volume and none of the clinical target volume may receive less than 79.2 Gy.
Study: NCT02533323

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: gemcitabine
Description: gemcitabine :1250mg/m2 (ivdrip) on days 1

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: oxaliplatin
Description: oxaliplatin :85 mg/m2 (ivdrip) on day 1

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: pegaspargase
Description: pegaspargase : 2500 IU/m2 (intramuscular injection)
Study: NCT01335178

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Intervention
Description: The intervention consisted of the following elements: (a) Three motivational interviews, scheduled for baseline, one month, and three months; (b) Feedback on air quality in the home (PM2.5 was measured using a Sidepak and/or a Dylos monitoring device, and air nicotine was measured using passive air nicotine dosimeters); (c) Feedback on child's exposure via hair nicotine; (d) a website designed especially for the project \[parents.org.il\];and (e) various self-help materials, including a booklet, a magnet about TSE, and air fresheners.
Study: NCT01437137

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: classic-laryngeal mask airway (c-LMA)
Description: Insertion of c-LMA

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: i-gel™
Description: Insertion of I-gel
Study: NCT03285334

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: XP-endo Shaper
Description: mechanical preparation in a 3D manner using Xp-endo Shaper

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: iRace files
Description: rotary mechanical preparation
Study: NCT02330250

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pharmaceutical Care
Description: The patients assigned for the intervention group will receive guidance from a pharmacist (pharmaceutical consultation) in addition to the medical care habitually delivered by the hospital.~The pharmacist will review the drug therapy, identifying current and potential problems related to the drug prescription, making a systematic assessment of the need, effectiveness and safety of all medications and their adequacy to the patient's life routine. A care plan will then be designed along with the patient that may include interventions and/or referral to other practitioners.

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Control
Description: The patients assigned to the control group will receive the medical care habitually provided by the hospital and will be attended by a non-pharmacist professional, who will provide hygiene/nutritional counseling and risk reduction, such as smoking cessation advice; use of estrogen-based contraceptive drugs; exposure to sunlight, proper use of sunscreen and clothes; nutritional guidance on the intake of low saturated-fat food. As usual, information about the use of medication will be provided by the attending physician.
Study: NCT03342326

Intervention type: OTHER
Group type: OTHER
Intervention: Exposure to familiar songs
Description: 3 conditions : a) Words and Music (sing condition), b) Words only (spoken condition) and c) Music only (instrumental condition) After each song : rate the popularity of the song on a scale of 1 to 5.

Intervention type: OTHER
Group type: OTHER
Intervention: Exposure to familiar songs
Description: 3 conditions : a) Words and Music (sing condition), b) Words only (spoken condition) and c) Music only (instrumental condition) After each song : rate the popularity of the song on a scale of 1 to 5.

Intervention type: OTHER
Group type: OTHER
Intervention: Music Experience Questionnaire
Description: questions about the past music training

Intervention type: OTHER
Group type: OTHER
Intervention: Music Experience Questionnaire
Description: questions about the past music training

Intervention type: OTHER
Group type: OTHER
Intervention: Implicit tasks memory
Description: 2 tests : a) Completion of trigrams : freely complete the first 3 letters of a word.~b) lexical decision : judge whether an audibly presented sound sequence is a word existing in the French language or not.

Intervention type: OTHER
Group type: OTHER
Intervention: Implicit tasks memory
Description: 2 tests : a) Completion of trigrams : freely complete the first 3 letters of a word.~b) lexical decision : judge whether an audibly presented sound sequence is a word existing in the French language or not.

Intervention type: OTHER
Group type: OTHER
Intervention: Questionnaires
Description: Mini Mental State Examination, 5 words by Dubois and fluence verbal test
Study: NCT03545737

Intervention type: OTHER
Intervention: Measurement
Description: The distances between the midpoint of the thyroid cartilage to suprasternal notch base on body surface measurement add the distance between suprasternal notch to carina of trachea according to chest CT

Intervention type: OTHER
Intervention: Formula
Description: The formula base on patient's height as a guide for the intubation of a Left-sided Double-lumen tube
Study: NCT04180189

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Weighted fiber blanket
Description: Using weighted blanket for four weeks

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Weighted fiber blanket
Description: Using weighted blanket for four weeks
Study: NCT04498156

Intervention type: OTHER
Intervention: No intervention
Description: No intervention, observational study

Intervention type: OTHER
Intervention: No intervention
Description: No intervention, observational study
Study: NCT02139605

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: D3 Lymphadenectomy
Description: D3 Lymphadenectomy involves surgical removal of lymph nodes from echelon or compartments 1 to 3 in gastric cancer patients
Study: NCT04746287

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CKD-510 multiple dose
Description: Investigational drug

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matching placebo
Study: NCT03611647

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Probiotic
Description: Probiotic dietary supplement containing a mixture of Lactobacillus and Bifidobacterium species, taken by mouth once daily for 4-6 weeks.

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo, taken by mouth once daily for 4-6 weeks.
Study: NCT03787940

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Isoniazid
Description: standard dose isoniazid or high dose isoniazid for participants with rapid acetylators

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Isoniazid
Description: standard dose isoniazid or high dose isoniazid for participants with rapid acetylators
Study: NCT00063947

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: erlotinib hydrochloride
Description: Given orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: gemcitabine hydrochloride
Description: Given IV

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: radiation therapy
Description: Undergo radiotherapy

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Correlative studies
Study: NCT02139605

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: D3 Lymphadenectomy
Description: D3 Lymphadenectomy involves surgical removal of lymph nodes from echelon or compartments 1 to 3 in gastric cancer patients
Study: NCT01133444

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Finasteride
Description: Finasteride tablets 1 mg
Study: NCT03081455

Intervention type: DIAGNOSTIC_TEST
Intervention: Diagnostic Test
Description: Genetic Diagnostic Testing
Study: NCT02152267

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: tDCS
Description: The transcranial direct current stimulation allows the neuronal membranes to neuromodulate and it can enhance or inhibit the potential actions on the cortex. Studies with animals has shown that anodal stimulation modulate the membrane in the way to depolarize which results in a long term potential in the stimulated area

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: tDCS
Description: The transcranial direct current stimulation allows the neuronal membranes to neuromodulate and it can enhance or inhibit the potential actions on the cortex. Studies with animals has shown that anodal stimulation modulate the membrane in the way to depolarize which results in a long term potential in the stimulated area

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: tDCS
Description: The transcranial direct current stimulation allows the neuronal membranes to neuromodulate and it can enhance or inhibit the potential actions on the cortex. Studies with animals has shown that anodal stimulation modulate the membrane in the way to depolarize which results in a long term potential in the stimulated area
Study: NCT02574546

Intervention type: PROCEDURE
Intervention: Mastectomy
Description: Unilateral breast cancers planning bilateral mastectomy procedures.
Study: NCT00656838

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Patients receives letter, phone call, office visit, educational materials
Description: Behavioral
Study: NCT03065894

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Matched Physical Therapy Intervention
Description: Patients who are medium-risk will receive up to 6-8 physical therapy (PT) visits over a 3 month period that is guided by published evidence based practice guidelines. The PT treatment will be tailored to the physical findings and specific patient needs, and appropriate exercises, spinal mobilization/manipulation, strengthening/stretching as well as a home program will be given to improve patient pain and function and reduce disability.~Patients who are high-risk will receive the evidence based PT treatment as deemed necessary. In addition, the PT treatment will incorporate principles of psychologically informed practice to address psychosocial barriers (e.g., fear avoidance, anxiety, etc) that may be impeding disability reduction. This may include instruction on chronic pain rehabilitation techniques such as the use of: pacing in order to maintain or increase activity; graded activity principles in order to increase function; and pain education and understanding responses to pain.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Current Care in Family Medicine
Description: Patient education, medication management
Study: NCT04383912

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Botox Injectable Product
Description: The side randomized to receive treatment will be injected with onabotulinum toxin A. Wound healing, scar characteristics, and patient satisfaction will be assessed post operatively. Scarring will be assessed by the patient, medical observers and a lay observer, all masked to the treatment vs placebo side. Standardized scales will be used, and pre-operative, intra-operative, and post-operative photographs will be taken for all participants. ImageJ software will be used to analyze the photos and measure the degree of brow lift achieved on each side, to ensure this has not been affected by onabotulinum toxin injection.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: No intervention (placebo)
Description: This group (of brows) will be receiving placebo injections containing normal saline. They will be assessed in the same manner as the treatment side.
Study: NCT01060215

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Normal saline
Description: 20 cc normal saline injection into the knee joint

Intervention type: PROCEDURE
Group type: NO_INTERVENTION
Intervention: Normal saline
Description: 20 cc normal saline injection into the knee joint
Study: NCT04985591

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Liposuction
Description: A small, inconspicuous incision was made in the liposuction group to dislodge fat out of the body.

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Other plastic surgery
Description: Other plastic surgery like blepharoplasty or keloid excision.
Study: NCT04303689

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Colchicine Tablets
Description: patients with essential hypertension are randomized to receive either 3 weeks of colchicine

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: patients with essential hypertension are randomized to receive either 3 weeks of placebo-treatment
Study: NCT04092868

Intervention type: OTHER
Intervention: Blood samples PK/ PD protamine
Description: PK/ PD protamine
Study: NCT02157935

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Symbicort
Description: Budesonide/formoterol pMDI, 160/4.5 μg x 2 actuations BID, for oral inhalation, 120 doses

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Formoterol turbohaler
Description: Formoterol Turbuhaler 4.5 μg x 2 actuations BID, for oral inhalation, 60 doses

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Placebo for Symbicort pMDI
Description: pMDI, aerosol for oral inhalation, placebo, 120 doses

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Placebo for Formoterol Turbohaler
Description: PLacebo powder for oral inhalation, 60 doses
Study: NCT03543748

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Transcranial Magnetic Stimulation
Description: A total of 2000 trains will be delivered successively. The pulses will be delivered at 80% of motor thresholds.

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham Transcranial Magnetic Stimulation
Description: The sham coil looks and sounds just like the real coil, but produces a negligible magnetic field.
Study: NCT01133444

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Finasteride
Description: Finasteride tablets 1 mg
Study: NCT02698631

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Conventional AF ablation
Description: Conventional AF ablation will be carried out according to the standard procedure. Atrial anatomical MRI information will be integrated into the navigation system. Ablation procedure will be carried out with a Smart Touch® catheter (temperature 45 °C, 40W or 30W for anterior or posterior wall, respectively).~Both in first and re-do procedures, procedure endpoint will be electrical isolation of all pulmonary veins.
Study: NCT02759900

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Non-thermal, atmospheric plasma to treat skin lesions and acne
Description: Non-thermal, atmospheric plasma treatment of affected area or lesions using a nanosecond dielectric barrier discharge plasma device
Study: NCT04440579

Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: Sham Percutaneous Tibial Nerve Stimulation (PTNS)
Description: Patients will be connected to the PTNS device but the device will remain off for the entirety of the procedure

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Standard Cystoscopy
Description: Patient will undergo standard cystoscopy

Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: Standard Cystoscopy
Description: Patient will undergo standard cystoscopy

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Standard Cystoscopy
Description: Patient will undergo standard cystoscopy
Study: NCT02698631

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: LGE-MRI guided AF ablation
Description: Post-processed LGE-MRI will be used to identify left atrial fibrotic patches and lesions surrounding pulmonary veins (re-do procedures). Both MRI atrial anatomical and fibrosis information will be integrated into the navigation system. Ablation procedures will be carried out with a SmartTouch® catheter (temperature 45°C, 40W or 30W for anterior or posterior wall, respectively).~* Procedural end-point for first ablation procedures will be isolation of all pulmonary veins, and encirclement and isolation of all atrial fibrotic areas.~* In re-do procedures, all left atrial fibrosis patches will be encircled and isolated and, for electrically non-isolated pulmonary veins, all anatomical gaps in lesions surrounding pulmonary veins (as identified in LGE-MRI) will be closed.
Study: NCT04881422

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: B-HIPE (Brief High Impact Preparatory Experience)
Description: The intervention consists in a one-week intensive rehabilitation in which participants underwent to a multidimensional rehabilitation composed by physical rehabilitation, mental wellbeing, a proper diet and engaging physical activity (a sail course). Digital motivating reinforcements are proposed to the participants with the aim to maintain the correct lifestyle learned in the B-HIPE program.
Study: NCT02135367

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: PRP
Description: injections of Platelet rich Plasma

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: PRP
Description: injections of Platelet rich Plasma